RecruitingPhase 2NCT07101744

Iparomlimab and Tuvonralimab Combined With Nimotuzumab in Recurrent or Metastatic NPC After First-line Treatment Failure: A Single-arm Phase IIa Clinical Trial

Studying Nasopharyngeal carcinoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Sun Yat-sen University
Intervention
Iparomlimab and Tuvonralimab(drug)
Enrollment
41 target
Eligibility
18-70 years · All sexes
Timeline
20252030

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07101744 on ClinicalTrials.gov

Other trials for Nasopharyngeal carcinoma

Additional recruiting or active studies for the same condition.

See all trials for Nasopharyngeal carcinoma

← Back to all trials